JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M411295200 on October 29, 2004

J. Biol. Chem., Vol. 280, Issue 2, 1408-1416, January 14, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/2/1408    most recent
M411295200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wreden, C. C.
Right arrow Articles by Reimer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wreden, C. C.
Right arrow Articles by Reimer, R. J.
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Varied Mechanisms Underlie the Free Sialic Acid Storage Disorders*{diamondsuit}

Christopher C. Wreden{ddagger}, Marcin Wlizla{ddagger}, and Richard J. Reimer§

From the Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305

Received for publication, October 4, 2004 , and in revised form, October 29, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Salla disease and infantile sialic acid storage disorder are autosomal recessive neurodegenerative diseases characterized by loss of a lysosomal sialic acid transport activity and the resultant accumulation of free sialic acid in lysosomes. Genetic analysis of these diseases has identified several unique mutations in a single gene encoding a protein designated sialin (Verheijen, F. W., Verbeek, E., Aula, N., Beerens, C. E., Havelaar, A. C., Joosse, M., Peltonen, L., Aula, P., Galjaard, H., van der Spek, P. J., and Mancini, G. M. (1999) Nat. Genet. 23, 462–465; Aula, N., Salomaki, P., Timonen, R., Verheijen, F., Mancini, G., Mansson, J. E., Aula, P., and Peltonen, L. (2000) Am. J. Hum. Genet. 67, 832–840). From the biochemical phenotype of the diseases and the predicted polytopic structure of the protein, it has been suggested that sialin functions as a lysosomal sialic acid transporter. Here we directly demonstrate that this activity is mediated by sialin and that the recombinant protein has functional characteristics similar to the native lysosomal sialic acid transport system. Furthermore, we describe the effect of disease-causing mutations on the protein. We find that the majority of the mutations are associated with a complete loss of activity, while the mutations associated with the milder forms of the disease lead to reduced, but residual, function. Thus, there is a direct correlation between sialin function and the disease state. In addition, we find with one mutation that the protein is retained in the endoplasmic reticulum, indicating that altered trafficking of sialin is also associated with disease. This analysis of the molecular mechanism of sialic acid storage disorders is a further step in identifying therapeutic approaches to these diseases.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Lysosomes are intracellular acidic organelles filled with hydrolytic enzymes. They are primarily responsible for the compartmentalized degradation of macromolecules as part of an intrinsic turnover process and as a mechanism for processing endocytosed nutrients. The importance of these organelles in normal cellular functions is apparent from the phenotype of a group of degenerative diseases designated as lysosomal storage disorders (3, 4). The hallmark of these disorders is the accumulation of material within enlarged lysosomes. The typical clinical phenotype is one of a progressive multiorgan involvement with a predominance of neurological dysfunction and often early death. For many of these diseases genetic studies have identified causative mutations, most of which occur in genes encoding enzymes involved in the hydrolysis of macromolecules.

The major products of the enzymatic processes in lysosomes are small organic molecules. While the membrane-bound nature of the organelle allows for hydrolytic enzymes to be isolated from the cytosol, it also requires mechanisms for the release of these end products. Biochemical studies have identified several lysosomal transport systems that facilitate the movement of amino acids, nucleotides, lipids, vitamins, and sugars across the lysosomal membrane (5, 6). However, the molecular identification of the lysosomal transport systems has been difficult. Their intracellular localization and the presence of lysosomes or an equivalent organelle in all eukaryotic cells have hampered the use of expression cloning. Genetic studies of lysosomal storage disorders have offered some insight into the molecular mechanisms of the transport processes. For example, the gene mutated in cystinosis has been shown to encode a lysosomal cystine transporter (7), while a fatty acid transporter (NPC1) localized to lysosomes and endosomes has been shown to be the product of a gene mutated in Niemann-Pick disease Type C (8, 9). Recent evidence also indicates that CLN3, the protein mutated in one form of Batten Disease, mediates a lysosomal arginine-H+ antiport activity (10).

Salla disease and infantile sialic acid storage disorder (ISSD)1 are autosomal recessive lysosomal storage disorders with common features but differing degrees of severity (1, 2). Salla Disease is characterized by developmental delay with marked cognitive and motor impairment noticeable at 6–12 months of age. However, many affected individuals reach adulthood (11). ISSD has a more severe phenotype with intrauterine hydrops, neonatal ascites, dysmorphic features, and death by 2 years of age. The cellular pathology for both diseases consists of enlarged lysosomes filled with high concentrations of free sialic acid, an amino sugar related to neuraminic acid (12–14). The free sialic acid is derived from the oligosaccharide chains of sialylated glycoproteins and glycolipids that have been degraded in the lysosme. Previous studies have demonstrated that individuals with Salla disease and ISSD accumulate free sialic acid in their lysosomes due to a defect in a proton-coupled sialic acid transport activity (14–16). Despite clear differences in the severity of the clinical phenotypes, both forms of the disease are associated with no detectable lysosomal sialic acid transport.

Genetic studies of individuals with Salla Disease led to the determination that a gene encoding a protein designated sialin contains the causative mutations (1). Sialin is a member of the anion/cation symporter (ACS) family of proteins and has a high degree of similarity to the vesicular glutamate transporters (VGUT1–3) (17). To date 16 mutations in sialin have been associated with the disease phenotype (2). The most common mutation (R39C) is found in Salla disease. The more severe ISSD is associated with four other missense mutations (K136E, H183R, P334R, G371V), a short deletion ({Delta}268–272), and 10 mutations that lead to early truncations or large deletions.

To better understand the mechanisms by which mutations may lead to disease, we sought to characterize the function of sialin. By altering a potential lysosomal targeting domain we are able to express the protein on the cell surface allowing for the use of whole cell uptake assays to measure transport activity. Using this approach we directly demonstrate that sialin is a sialic acid transporter with characteristics similar to those of the native lysosomal transport system. Through characterizing the effect of disease-associated mutations on transport activity we show a direct correlation between the degree of transport activity lost and the severity of the clinical phenotype. In addition, we demonstrate that one mutation leads to retention of the protein in the endoplasmic reticulum, suggesting that altered trafficking of sialin can also contribute to the pathophysiology of these disorders.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Isolation of Rat Sialin cDNA and Mutagenesis—The predicted human sialin peptide sequence was used to identify expressed sequence tags (ESTs) in the rat sequence data base (NCBI). Oligonucleotides corresponding to the 5' and 3' ends of the coding sequence were generated and high fidelity PCR (Turbo Pfu, Stratagene) was used to amplify the sequence from PC12 cell cDNA. The cDNA was subcloned into the expression vector pcDNA3 (Invitrogen). To introduce disease-associated mutations and restriction sites for epitope tagging, site-directed mutagenesis was carried out with the QuikChange kit (Stratagene) following the directions of the manufacturer. The DNA was submitted to a commercial sequence facility for ABI automated sequencing to confirm generation of the desired mutation. To facilitate the generation of a subset of constructs an NheI site was introduced into the amino-terminal portion of the protein resulting in a conservative mutation (N41G), which did not alter the localization or function of the protein.

Cell Culture and Heterologous Expression—HeLa cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) with 10% Cosmic-calf serum (Hyclone). All cultures were kept at 37 °C in 5% CO2, and all media contained penicillin and streptomycin. To transiently express cDNAs in HeLa cells, Effectene (Qiagen) was used according to the instructions of the manufacturer. For cotransfection, equal amounts of DNA were used with the total amount corresponding to that recommended by the manufacturer.

Immunofluorescence of Cultured Cells—HeLa cells were plated at 80,000 per well in 24-well plates. Approximately 20 h later the cells were transfected as described above and the following day split ~1:3 onto glass coverslips pretreated with poly-D-lysine (Sigma). Immunofluorescence staining was carried out as described previously (18) and coverslips mounted on glass slides using Mowiol (Calbiochem). The rabbit anti-HA antibody (Abcam) was used at 1:2,000 and the mouse anti-PDI antibody (Stressgen) was used at 1:50. Secondary antibodies labeled with Alexa 488 or Alexa 568 (Molecular Probes) were diluted at 1:1,000. Zeiss Axiovert 100M inverted microscope configured for confocal microscopy (LSM 5 PASCAL, Zeiss) was used for imaging.

Transport Assay—HeLa cells were plated on 24-well plates at a density of 70,000 per well and the following day transfected as described above. After 24–36 h, transport assays with radiolabeled N-acetylneuraminic acid (0.05 µCi/well (~3.6 µM final concentration)) (American Radiolabeled Chemicals) were carried out as described previously (19). For controls LYAAT1, a lysosomal transporter previously characterized with whole cell uptake assays (19), was used and the background was subtracted for saturation, inhibition, and pH dependence studies. Statistical analyses were performed using the Prism program (GraphPad Software). For the time course each point is the mean of two separate samples. For all other experiments results are from four experiments with error bars indicating the standard error of the mean.

Labeling of Cell Surface Proteins—Cells in the wells of a 24-well plate were rinsed twice with CMF-PBS and then 300 µl of CMF-PBS with 5 mM EDTA was added to each well. Cells were triturated and samples from 3 wells were combined. After centrifugation at 800 x g the cells were rinsed with 500 µl of ice-cold borate buffered saline (50 mM borate, 150 mM NaCl, pH 8.2) and then incubated in 125 µl of 2 mM sulfo-NHS-LC-Biotin (Pierce) in borate buffered saline for 30 min on ice. 500 µl of CMF-PBS with 10 mM glycine was then added to quench the labeling reaction. After pelleting the cells, biotinylated proteins were isolated on NeutrAvadin beads (Pierce) as described previously (20).

Western Analysis—Samples were separated on an SDS-polyacrylamide gel, transferred to polyvinylidene difluoride membranes (Pall), and immunoblotted as described previously (21). Detection of hybridization was done with enhanced chemiluminescence (Amersham Biosciences) and exposure of the blot to autoradiography film (Cole Parmer Blue-Sensitive) for 15 s to 5 min. The rabbit anti-HA antibody (Chemicon) was used at 1:1,000, and the horseradish peroxidase-linked anti-rabbit antibody (Pierce) was used at 1:10,000.

Determination of Relative Specific Transport Activity—To determine relative specific activity, transport activity and quantitative analysis of cell surface expression were carried out in parallel experiments for the wild-type, R39C, and K136E mutants with the dileucine motifs disrupted. Transport was measured at 3 min as described above. For quantification of cell surface protein expression Western blots were scanned and converted to a TIFF file for analysis. Regions of interest were identified and quantified in density units using NIH Image. The corresponding region in a lane with a sample from cells transfected the untagged LYAAT1 protein was measured as background and subtracted from all values. Relative specific activity for each mutant was calculated from the following equation: [uptake by mutant (pmols/3 min)/uptake by wild type (pmols/3 min)]/[mutant expression level (density units)/wild-type expression level (density units)].


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Mutations Associated with Disease Occur in Conserved Residues—To facilitate the characterization of the physiological role of sialin we identified a rat orthologue of the human protein. A BLAST search of available rat ESTs led to the identification of separate ESTs corresponding to the 5' and 3' ends of the rat sialin cDNA. Oligonucleotide primers were designed to generate a sequence corresponding to the open reading frame of the cDNA. Amplification of the sequence generated a cDNA that predicts a 495-amino acid peptide with 12 transmembrane domains and 86% identity and 90% similarity to the human protein. A similar degree of homology is also noted in comparisons of the rat or human sequences to the identified murine or ovine sequences (Fig. 1).



View larger version (101K):
[in this window]
[in a new window]
  		FIG. 1.
Disease-associated mutations occur in highly conserved residues. The predicted human, rat, mouse and sheep sialin amino acid sequences are compared using the Pileup program (GCG version 10.1). Black shaded boxes indicated identity, gray boxes similarity. Missense mutations (R39C, K136E, H183R, P334R and G371V) are indicated by the individual letters above the corresponding residues in the pileup. The short deletion ({Delta}268–272) is indicated above the deleted amino acids. Predicted transmembrane domains (TOPPRED-GES) are indicated by the gray bars above the corresponding residues. Residues predicted to undergo N-glycosylation (N59; N71; N77; N95; N225; N302; N357), CAM kinase dependent phosphorylation (S256), Protein Kinase C dependent phosphorylation (T17; S37; T79; T97; S269; S276) and Casein kinase II dependent phosphorylation (T72; S259; T452) are conserved to varying degrees among the mammalian orthologues.

 
Sequence comparison of the mammalian proteins indicates that the disease-causing point mutations occur throughout the protein with no obvious clustering. The predicted topology suggests that the mutations occur in residues within (H183R, P334R, and G371V) or abutting (R39C, K136E) transmembrane domains. In contrast, the amino acids excised in the short deletion are in the middle of a well defined extramembraneous region. The residues associated with the mutations are highly conserved among the mammalian proteins; the only variation is a single conservative substitution in the deleted segment of one species. The absence of structure-function analysis of sialin or related proteins precludes predictions about the influence of the mutations based on their location in the protein.

Disruption of Putative Adaptor Protein-binding Domain Leads to Plasma Membrane Expression of Sialin—Measuring transport activity of recombinant sialin is complicated by the fact that the protein is likely expressed in all cells of higher eukaryotic organisms. To circumvent the problem of endogenous lysosomal sialic acid transport activity we sought to generate a form of sialin that traffics to the cell surface, thus allowing for whole cell uptake assays to measure activity of the recombinant protein. While a plasma membrane sialic acid transport activity has been described (22), we found no measurable uptake in intact HeLa cells, suggesting that this approach would be feasible.

In analyzing sialin sequences from different species we noted a short sequence (DXXPLL) in the cytosolic amino terminus that is conserved from Xenopus laevis to humans (Fig. 2A). A dileucine with an acidic amino acid 4 residues upstream is a consensus motif for adaptor protein (AP) binding (23). Since interactions with AP1 or AP3 are required for proper targeting of some lysosomal membrane proteins (23), we sought to determine whether this domain in sialin is involved in trafficking. We first replaced the amino-terminal cytosolic domain of sialin, containing the motif, with the corresponding region of NaPi-1, a structurally related protein that resides on the plasma membrane (24). When heterologously expressed in HeLa cells, the HA-tagged chimeric protein no longer displays a pattern of large puncta typical of lysosomal antigens but stains finer structures within the cell. It also appears to be present on the plasma membrane (Fig. 2B). To further refine the sequence necessary for lysosomal targeting, in separate constructs we mutated the leucines and altered the spacing between the leucines and the acidic residue. These changes have been shown to disrupt the interaction of the lysosomal protein LIMP2 with AP3 and to alter targeting of the protein (25). Replacing both leucines with alanines (L22A,L23A) or inserting two additional amino acids (alanines) between the acidic residue and the dileucine of sialin (20AAins21) resulted in an expression pattern similar to the NaPi-1-sialin chimera, indicating that this specific motif within the amino terminus facilitates lysosomal targeting of sialin (Fig. 2B).



View larger version (50K):
[in this window]
[in a new window]
  		FIG. 2.
A putative adaptor protein-binding domain is involved in sialin trafficking. A, pileup (GCG version 10.1) of the amino termini of five vertebrate species demonstrates that a putative dileucine based AP-binding domain ([D/E]XXXL[L/I]) is highly conserved. B, confocal images of immunofluorescence staining for wild-type (WT) HA tagged sialin demonstrate large puncta consistent with lysosomes (arrows). Expression of sialin constructs in which the N terminus (N-term) has been replaced with that of NaPi-1 or in which the putative AP-binding domain has been disrupted yields staining of finer structures within cells as well as the plasma membrane (arrowheads). For the mutated putative AP-binding domains insertions or substitutions are in red. NaPi-1 does not contain a putative AP-binding site. The asterisk indicates the position of the Salla mutation (R39C). The scale bar indicates 25 µM.

 
Sialin Is a pH-dependent Sialic Acid Transporter—Disruption of the targeting sequence enables measurements of activity at the plasma membrane through whole cell uptake assays. The orientation of the protein, with the lumenal side facing out, is such that whole cell uptake corresponds to the transport of sialic acid out of the lysosome. Transporters are often reversible, but asymmetries in relative affinity can exist at the two sides of the transporter. Even though the physiologically relevant activity for the lysosomal sialic acid transport system is to mediate the outward movement of sialic acid, the most comprehensive studies on the native transport system have relied on the reversibility of the transport system and measured uptake into intact lysosomes (26–28). With sialin mistargeted to the cell surface, however, the activity measured will more directly reflect the physiologically relevant function of the protein.

For initial studies, to make the extracellular environment approximate the acidic lysosomal lumen, the cells were incubated in a Krebs-Ringer solution buffered with MES at pH 5.5. A marked time-dependent increase in the uptake of sialic acid is seen in cells expressing plasma membrane targeted sialin compared with cells expressing another lysosomal transporter protein, LYAAT1 (Fig. 3, A and B). The activity is saturable with a Km of ~0.8 mM, which is similar to, but slightly higher than, the value reported for the uptake of sialic acid into lysosomes (Fig. 3C). Sialic acid uptake is not affected by switching to a Na+- and Cl--free MES-buffered sucrose solution (data not shown), indicating that the activity is not dependent on, or inhibited by, either of these ions. However, uptake is reduced by two known inhibitors of lysosomal sialic acid uptake, glucuronic acid and DIDS (Fig. 3D).



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 3.
Sialin mediates sialic acid transport. Radiolabeled sialic acid (N-acetylneuraminic acid (NANA)) uptake was measured in HeLa cells expressing sialin with a LL22,23AA mutation (sialin) or an unrelated lysosomal neutral amino acid transporter (LYAAT1). A, uptake measured at 5 min demonstrates a greater than 5-fold increase in the sialin expressing cells compared with LYAAT1 expressing cells. B, sample time course indicates that uptake is maximal near 5 min. C, a representative measurement of transport during the linear phase of uptake (2 min) with increasing concentrations of unlabeled sialic acid demonstrates a saturable activity. The apparent Km is 0.73 ± 0.16 mM. D, addition of glucuronic acid (10 mM) and DIDS (2 mM) to uptake buffer demonstrates marked inhibition by glucuronic acid and less, but significant, inhibition by DIDS. E, uptake at 5 min under varied buffer pH demonstrates that transport is dependent on the external pH with uptake at pH 5.5 >> pH 6.5 >> pH 7.5. F, transport at 5 min in the presence of the K+/H+ exchanger nigericin (nig) and/or the K+ ionophore valinomycin (val) at pH 5.5 demonstrates that transport is markedly reduced by disrupting the transmembrane proton electrochemical gradient (nigericin plus valinomycin) or the pH gradient alone (nigericin) but not by isolated reduction in the membrane potential (valinomycin).

 
A large pH gradient exists across the lysosomal membrane and several lysosomal transport systems, including the sialic acid transport system, are coupled to this gradient. To determine the role of pH in the activity of the recombinant protein, both the pH of the buffer solution and the pH gradient across the plasma membrane were varied. Increasing the buffer pH from 5.5 to 6.5 markedly decreases sialin mediated transport, and essentially no transport is detected when the extracellular solution is buffered at approximately the same pH as the cytoplasm (pH 7.5) (Fig. 3E). In addition, uptake is reduced by ~80% at pH 5.5 by abolishing the pH gradient with nigericin, an ionophore that mediates H+/K+ exchange (Fig. 3F). On the other hand, transport activity is not affected by specific dissipation of the electrical gradient using the K+ ionophore valinomycin, suggesting that transport is electroneutral.

A Subset of Mutations Is Associated with Residual Transport Activity—After confirming that sialin is a sialic acid transporter, we next sought to determine whether mutations associated with disease alter the intrinsic transport activity of the protein. To do this, we disrupted the putative AP-binding domain of proteins containing the disease-associated mutations (R39C, K136E, H183R, P334R, G371V, and {Delta}268–272(SSLRN)). This leads to plasma membrane expression of all of the proteins with the exception of G371V, as indicated by the pattern of immunofluorescence staining (Fig. 4A) and cell surface biotinylation (data not shown). Measuring total uptake at 5 min (Fig. 4B) demonstrates that the transport activity of the R39C and K136E mutants is reduced. Whereas, essentially no transport activity can be detected for the other mutants (H183R, P334R, G371V, and {Delta}268–272(SSLRN)). The absence of measurable activity associated with the H183R and P334R mutations and the short deletion despite plasma membrane expression strongly suggests that these mutations abolish transporter activity. However, since G371V is not present at detectable levels on the plasma membrane, with this approach we cannot determine whether the mutation influences the intrinsic transport activity of the protein.



View larger version (59K):
[in this window]
[in a new window]
  		FIG. 4.
A subset of disease-associated mutations lead to a partial loss of transport activity. Amino acid changes corresponding to disease-associated mutations were made in sialin in tandem with the dileucine to dialanine mutation in the putative AP-binding domain. A, immunofluorescence staining of the HA-tagged proteins suggests plasma membrane expression of some of the mutants with the exception of G371V. B, uptake at pH 5.5 after 5-min incubation indicates that R39C and K136E retain some transport activity, while minimal activity is associated with the other mutations. C, specific activity for R39C and K136E relative to wild-type indicates that both mutations lead to loss of ~90% of the activity associated with the wild-type protein. Relative specific activity was determined as described under "Experimental Procedures." The scale bar in A indicates 25 µM.

 
Although a partial reduction in transport activity could lead to disease, the absence of a phenotype in heterozygote carriers of the free sialic acid storage disorders, who have approximately half the normal lysosomal sialic acid transport activity (27), suggests that activity would need to be reduced by more than 50%. Therefore, we wanted to know, more precisely, the effect of the R39C and K136E mutations on activity. To accomplish this, we analyzed sialic acid uptake relative to the amount of biotinylated cell surface protein expresssion. For both mutants, uptake and plasma membrane expression were determined relative to transfected wild-type protein. Normalizing relative uptake to relative biotinylated cell surface expression demonstrates that both the Salla mutation and the K136E mutation retain only about 10% of their intrinsic transport activity (Fig. 4C).

The G371V Mutation Leads to Retention of Sialin in the ER—In a previous report in which the localization of sialin was compared with LAMP1, a lysosomal/late endosomal marker, recombinant proteins with the Salla mutation and the short deletion were found to be mislocalized, leading the authors to suggest that improper targeting could contribute to the defect associated with these mutations (29). In trying to determine the extent to which other mutations influence trafficking of sialin we found that wild-type sialin only partially localizes with LAMP1 and LAMP2 in HeLa cells (data not shown), suggesting that colocalization studies with these endogenous antigens would be difficult. Therefore, to determine whether mutations affect trafficking we compared wild-type and mutant proteins expressed in the same cell using differential epitope tagging.

As expected, simultaneous expression of HA-tagged and Myc-tagged wild-type sialin leads to colocalization of the two epitopes by immunofluoresence staining (Fig. 5A). Analysis of cells cotransfected with Myc-tagged wild-type sialin and HA-tagged R39C mutant demonstrates a predominant staining pattern of complete overlap with only rare cells with partial overlap (Fig. 5A). This colocalization is independent of expression levels or time after transfection (data not shown). Similar colocalization with the wild-type protein is seen with other mutants including K136E, H183R, P334R, and the short deletion (Fig. 5A).



View larger version (51K):
[in this window]
[in a new window]
  		FIG. 5.
G371V mutation is associated with retention in the endoplasmic reticulum. A, HA-tagged proteins with disease-associated mutations (middle column) were coexpressed with Myc-tagged wild-type sialin (left column) in HeLa cells. Overlay of confocal images (right column) demonstrates that proteins with the R39C, K136E, H183R, and P334R mutations, as well as the short deletion, colocalize with the wild-type protein. B, a marked difference in staining patterns is demonstrated for G371V. Double labeling studies with PDI, an endoplasmic reticulum marker, suggests that G371V is retained in the ER. The scale bars indicate 10 µM.

 
A striking differential localization is only seen for G371V. This mutant colocalizes with PDI, an endoplasmic reticulum protein, suggesting retention in this compartment (Fig. 5B). Interestingly the combination of G371V with the disrupted putative AP-binding domain also colocalizes with PDI (data not shown), consistent with sialin interacting with an adaptor protein in a post-ER compartment.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Characterization of the biochemical phenotype of Salla disease and infantile sialic acid storage disorder led to the identification of a lysosomal sialic acid transport activity (15, 26), and subsequent genetic studies suggested that sialin, the protein mutated in these diseases, mediates this activity (1). Here we present data supporting a direct role for sialin in sialic acid transport and describe the effects of disease-associated mutations on the transport activity and trafficking of the protein.

The analysis of the sialin sequence from different species highlights two interesting points. First, the missense mutations associated with Salla disease and ISSD occur in absolutely conserved residues within or abutting transmembrane domains. This degree of conservation is consistent with these residues playing a crucial role in the function of the protein. Furthermore, the association of these residues with membranous segments of the protein fits with a role in recognition or translocation of the substrate or in the proper folding of the protein within the membrane.

The second point derived from a comparison of the sequences is the presence of a conserved putative AP-binding domain in the amino terminus of sialin. The motif, an acidic amino acid four residues upstream of a dileucine, is similar to domains required for interactions between adaptor proteins and their binding partners, including the interaction between AP3 and the lysosomal protein LIMP2 (23, 25). Replacing the entire amino terminus, mutating the dileucine residues, or inserting two additional amino acids between the dileucine and the requisite upstream acidic residue all increase plasma membrane expression of sialin. In addition, a phosphorylatable residue precedes the consensus motif in all of the mammalian sialin sequences. Interestingly a serine precedes similar dileucine motifs in the CD3-{gamma} chain of the T-cell receptor (SDKQTLL) and the CD4 coreceptor (SQIKRLL) (30–32). Phosphorylation of these serines induces a rapid internalization of the proteins and targeting to lysosomes where the proteins are degraded. If localization of sialin is controlled in a manner parallel to these highly regulated components of receptors, it suggests that the function of sialin may be more complex than simply mediating the efflux of a degradative product from lysosomes.

The plasma membrane localization associated with the altered amino terminus enabled us to measure transport, not in lysosomes, but at the cell surface, thus circumventing the background activity associated with endogenously expressed sialin. The transport activity of the recombinant sialin retains the essential characteristics of the previously described native lysosomal sialic acid transport activity (26, 28), confirming the predicted role for the protein. The transport activity is inhibited by glucuronic acid, an acidic sugar that is a competitive inhibitor of the lysosomal sialic acid transport. Although it occurs less commonly in glycoproteins and glycolipids, glucuronic acid is also a physiological substrate for the transporter and accumulates in the lysosomes of individuals with the free sialic acid storage disorders (26, 33). The stilbene derivative DIDS, a anion channel blocker, inhibits VGLUT1 transport function (34) as well as sialin-mediated transport.

Lysosomal transport systems can mediate facilitated diffusion or can be coupled to the proton electrochemical gradient through proton cotransport. Our data and previous data on the lysosomal transport system (26) suggest that sialin is directly coupled to the proton gradient and that there is a 1:1 stoichiometry between the sugar and protons. However, whether or not sialin plays a significant role in regulating lysosomal pH, either through coupled movement of protons (as has been suggested for the lysosomal arginine transporter CLN3 (35, 36)) or through an anion conductance (as has been described for the structurally related NaPi-1 and VGLUT1 (24, 34, 37)), remains to be determined.

For sialin to carry out its predicted function it must be localized to lysosomes, have an appropriate affinity for sialic acid, and couple sialic acid movement to the cotransport of protons. Therefore, mutations that lead to disease can mediate their effects through a variety of mechanisms. While large deletions and truncations are likely to lead to a marked reduction or absence of the protein, point mutations may lead to altered transport activity or influence stability and/or trafficking of the protein. In analyzing the effect of the disease mutations on transport function we found that the Salla (R39C) and K136E mutants retain low levels of intrinsic activity. Whereas, for H183R, P334R, and {Delta}268–272(SSLRN) no activity could be detected despite plasma membrane expression of the proteins. G371V appears to be retained in the ER so it is impossible to determine its activity by plasma membrane uptake assays.

For the mutants with no transport activity, the molecular mechanisms leading to loss of function remain to be determined. Some possibilities are suggested by the residues in which the mutations occur. For example, histidine has a pKa of ~6.0, suggesting that within a physiologically relevant pH range His183, which lies within a predicted transmembrane domain, could accept and transfer protons. Indeed, in other proton-coupled transporters histidine residues within membranous segments have been implicated in proton transfer (38, 39). Interestingly, the corresponding mutation in the related VGLUT1 retains activity.2 Although VGLUT1-mediated transport is driven by a proton electrochemical gradient, it is dependent on the electrical, not the chemical component, suggesting that its transport activity does not involve proton movement (34). Thus, His183 may be directly involved in proton coupling, a mechanism necessary for sialin function but not VGLUT1 function.

As an underlying mechanism by which mutations lead to a loss of function, residue changes may alter the structure or stability of the proteins. For instance, the short deletion may interfere with proper folding of the protein by limiting the flexibility between the predicted transmembrane domains that the loop appears to bridge. In addition, both proline and glycine residues are important in transmembrane protein structure; prolines are helix-breaking residues often occurring at the ends of transmembrane segments, and glycines can allow for appropriate packing of transmembrane domains (40). This suggests that the effect of the P334R and G371V mutations may be on the tertiary structure of sialin. Interestingly, ER retention, as seen with the G371V mutation, is common to disease-causing mutations in two other polytopic proteins, CFTR and aquaporin-2 (41–43). Recently, in an animal model with mutant CFTR, inhibition of an ER-associated degradation has been shown to increase expression levels and ameliorate the phenotype of the disease (44, 45). Whether or not a similar effect occurs for the G371V mutation in sialin remains to be determined.

Perhaps most interesting are the results of our analysis of the Salla disease mutation (R39C) and the K136E mutation. In each case, residual activity is clearly present, and each protein appears to colocalize with the wild-type protein, suggesting proper trafficking. It is important to note that both mutations are associated with milder forms of the disease (2). The K136E mutation has only been reported in a single case, in a compound heterozygous individual with the R39C mutation where the clinical phenotype was intermediate between Salla disease and ISSD. Compared with ISSD, Salla disease is clinically less severe and is associated with lower levels of free sialic acid in both urine and cells cultured from patients. An unresolved issue has been the difference in phenotypes for Salla disease and ISSD, despite a complete absence of measurable sialic acid transport activity in lysosomes derived from patients with both diseases (15, 16, 27). Although this has been attributed to a lack of sensitivity in the methods used to measure lysosmal transport activity, some uncertainty has persisted. Our data demonstrating that the Salla mutation retains residual activity reconcile this issue and further suggest that there is a direct correlation between clinical phenotype and transporter function.

In characterizing the function of sialin, we have advanced our understanding of the mechanisms that underlie Salla disease and ISSD. We have demonstrated both a direct role for the protein in the transmembrane transport of sialic acid and a loss or severe reduction in transport activity in several different disease-associated mutations. The loss of intrinsic function suggests crucial roles in the transport process for the mutated residues, and further comparison of the effect of similar mutations in the related vesicular glutamate transporters may reveal important mechanistic differences among these structurally related, but functionally divergent, proteins. In addition, the retained activity associated with specific mutations suggests that therapeutic approaches directed at increasing the expression or stability of sialin may prove beneficial in these cases.


   FOOTNOTES
 
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AY800277 [GenBank] .

* This work was supported by a Basil O'Connor Grant from the March of Dimes and by National Institutes of Health Grant NS045634-01. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{diamondsuit} This article was selected as a Paper of the Week. Back

{ddagger} These authors contributed equally to this work. Back

§ To whom correspondence should be addressed. Tel.: 650-724-4179; Fax: 650-498-6262; E-mail: rjreimer{at}stanford.edu.

1 The abbreviations used are: ISSD, infantile sialic acid storage disorder; EST, expressed sequence tag; HA, hemagglutinin; AP, adaptor protein; MES, 4-morpholineethanesulfonic acid; DIDS, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid; ER, endoplasmic reticulum; PDI, protein disulfide-isomerase. Back

2 R. J. Reimer and A. Lin, unpublished observations. Back


   ACKNOWLEDGMENTS
 
We acknowledge Craig Garner, William Mobley, Robert Edwards, Angela Hahn, Ellie Heckscher, members of the Meyer laboratory, and members of the Garner laboratory for assistance and guidance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Verheijen, F. W., Verbeek, E., Aula, N., Beerens, C. E., Havelaar, A. C., Joosse, M., Peltonen, L., Aula, P., Galjaard, H., van der Spek, P. J., and Mancini, G. M. (1999) Nat. Genet. 23, 462-465[CrossRef][Medline] [Order article via Infotrieve]
  2. Aula, N., Salomaki, P., Timonen, R., Verheijen, F., Mancini, G., Mansson, J. E., Aula, P., and Peltonen, L. (2000) Am. J. Hum. Genet. 67, 832-840[CrossRef][Medline] [Order article via Infotrieve]
  3. Schiffmann, R., and Brady, R. O. (2002) Drugs 62, 733-742[CrossRef][Medline] [Order article via Infotrieve]
  4. Moser, H. W. (1992) Curr. Opin. Neurol. Neurosurg. 5, 355-358[Medline] [Order article via Infotrieve]
  5. Pisoni, R. L., and Thoene, J. G. (1991) Biochim. Biophys. Acta 1071, 351-373[Medline] [Order article via Infotrieve]
  6. Mancini, G. M., Havelaar, A. C., and Verheijen, F. W. (2000) J. Inherit. Metab Dis. 23, 278-292[CrossRef][Medline] [Order article via Infotrieve]
  7. Town, M., Jean, G., Cherqui, S., Attard, M., Forestier, L., Whitmore, S. A., Callen, D. F., Gribouval, O., Broyer, M., Bates, G. P., van't Hoff, W., and Antignac, C. (1998) Nat. Genet. 18, 319-324[CrossRef][Medline] [Order article via Infotrieve]
  8. Davies, J. P., Chen, F. W., and Ioannou, Y. A. (2000) Science 290, 2295-2298[Abstract/Free Full Text]
  9. Loftus, S. K., Morris, J. A., Carstea, E. D., Gu, J. Z., Cummings, C., Brown, A., Ellison, J., Ohno, K., Rosenfeld, M. A., Tagle, D. A., Pentchev, P. G., and Pavan, W. J. (1997) Science 277, 232-235[Abstract/Free Full Text]
  10. Kim, Y., Ramirez-Montealegre, D., and Pearce, D. A. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 15458-15462[Abstract/Free Full Text]
  11. Varho, T. T., Alajoki, L. E., Posti, K. M., Korhonen, T. T., Renlund, M. G., Nyman, S. R., Sillanpaa, M. L., and Aula, P. P. (2002) Pediatr. Neurol. 26, 267-273[CrossRef][Medline] [Order article via Infotrieve]
  12. Aula, P., Autio, S., Raivio, K. O., Rapola, J., Thoden, C. J., Koskela, S. L., and Yamashina, I. (1979) Arch. Neurol. 36, 88-94[Abstract]
  13. Virtanen, I., Ekblom, P., Laurila, P., Nordling, S., Raivio, K. O., and Aula, P. (1980) Pediatr. Res. 14, 1199-1203[Medline] [Order article via Infotrieve]
  14. Renlund, M., Aula, P., Raivio, K. O., Autio, S., Sainio, K., Rapola, J., and Koskela, S. L. (1983) Neurology 33, 57-66[Abstract/Free Full Text]
  15. Renlund, M., Tietze, F., and Gahl, W. A. (1986) Science 232, 759-762[Abstract/Free Full Text]
  16. Tietze, F., Seppala, R., Renlund, M., Hopwood, J. J., Harper, G. S., Thomas, G. H., and Gahl, W. A. (1989) J. Biol. Chem. 264, 15316-15322[Abstract/Free Full Text]
  17. Reimer, R. J., and Edwards, R. H. (2004) Pfluegers Arch 447, 629-635[CrossRef][Medline] [Order article via Infotrieve]
  18. Kent, H. M., McMahon, H. T., Evans, P. R., Benmerah, A., and Owen, D. J. (2002) Structure (Camb.) 10, 1139-1148[Medline] [Order article via Infotrieve]
  19. Wreden, C. C., Johnson, J., Tran, C., Seal, R. P., Copenhagen, D. R., Reimer, R. J., and Edwards, R. H. (2003) J. Neurosci. 23, 1265-1275[Abstract/Free Full Text]
  20. Seal, R. P., Leighton, B. H., and Amara, S. G. (2000) Neuron 25, 695-706[CrossRef][Medline] [Order article via Infotrieve]
  21. Chaudhry, F. A., Reimer, R. J., Bellocchio, E. E., Danbolt, N. C., Osen, K. K., Edwards, R. H., and Storm-Mathisen, J. (1998) J. Neurosci. 18, 9733-9750[Abstract/Free Full Text]
  22. Hirschberg, C. B., Goodman, S. R., and Green, C. (1976) Biochemistry 15, 3591-3599[CrossRef][Medline] [Order article via Infotrieve]
  23. Bonifacino, J. S., and Traub, L. M. (2003) Annu. Rev. Biochem. 72, 395-447[CrossRef][Medline] [Order article via Infotrieve]
  24. Busch, A. E., Schuster, A., Waldegger, S., Wagner, C. A., Zempel, G., Broer, S., Biber, J., Murer, H., and Lang, F. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5347-5351[Abstract/Free Full Text]
  25. Sandoval, I. V., Martinez-Arca, S., Valdueza, J., Palacios, S., and Holman, G. D. (2000) J. Biol. Chem. 275, 39874-39885[Abstract/Free Full Text]
  26. Mancini, G. M., de Jonge, H. R., Galjaard, H., and Verheijen, F. W. (1989) J. Biol. Chem. 264, 15247-15254[Abstract/Free Full Text]
  27. Mancini, G. M., Beerens, C. E., Aula, P. P., and Verheijen, F. W. (1991) J. Clin. Invest. 87, 1329-1335[Medline] [Order article via Infotrieve]
  28. Havelaar, A. C., Beerens, C. E., Mancini, G. M., and Verheijen, F. W. (1999) FEBS Lett. 446, 65-68[CrossRef][Medline] [Order article via Infotrieve]
  29. Aula, N., Jalanko, A., Aula, P., and Peltonen, L. (2002) Mol. Genet. Metab. 77, 99-107[CrossRef][Medline] [Order article via Infotrieve]
  30. Dietrich, J., Hou, X., Wegener, A. M., and Geisler, C. (1994) EMBO J. 13, 2156-2166[Medline] [Order article via Infotrieve]
  31. von Essen, M., Menne, C., Nielsen, B. L., Lauritsen, J. P., Dietrich, J., Andersen, P. S., Karjalainen, K., Odum, N., and Geisler, C. (2002) J. Immunol. 168, 4519-4523[Abstract/Free Full Text]
  32. Pitcher, C., Honing, S., Fingerhut, A., Bowers, K., and Marsh, M. (1999) Mol. Biol. Cell 10, 677-691[Abstract/Free Full Text]
  33. Blom, H. J., Andersson, H. C., Seppala, R., Tietze, F., and Gahl, W. A. (1990) Biochem. J. 268, 621-625[Medline] [Order article via Infotrieve]
  34. Bellocchio, E. E., Reimer, R. J., Fremeau, R. T., Jr., and Edwards, R. H. (2000) Science 289, 957-960[Abstract/Free Full Text]
  35. Golabek, A. A., Kida, E., Walus, M., Kaczmarski, W., Michalewski, M., and Wisniewski, K. E. (2000) Mol. Genet. Metab. 70, 203-213[CrossRef][Medline] [Order article via Infotrieve]
  36. Pearce, D. A., Ferea, T., Nosel, S. A., Das, B., and Sherman, F. (1999) Nat. Genet. 22, 55-58[CrossRef][Medline] [Order article via Infotrieve]
  37. Bröer, S., Schuster, A., Wagner, C. A., Bröer, A., Forster, I., Biber, J., Murer, H., Werner, A., Lang, F., and Busch, A. E. (1998) J. Membr. Biol. 164, 71-77[CrossRef][Medline] [Order article via Infotrieve]
  38. Chen, X. Z., Steel, A., and Hediger, M. A. (2000) Biochem. Biophys. Res. Commun. 272, 726-730[CrossRef][Medline] [Order article via Infotrieve]
  39. Kaback, H. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5539-5543[Abstract/Free Full Text]
  40. Ulmschneider, M. B., and Sansom, M. S. (2001) Biochim. Biophys. Acta. 1512, 1-14[Medline] [Order article via Infotrieve]
  41. Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., and Grinstein, S. (1994) EMBO J. 13, 6076-6086[Medline] [Order article via Infotrieve]
  42. Pasyk, E. A., and Foskett, J. K. (1995) J. Biol. Chem. 270, 12347-12350[Abstract/Free Full Text]
  43. Tamarappoo, B. K., and Verkman, A. S. (1998) J. Clin. Invest. 101, 2257-2267[Medline] [Order article via Infotrieve]
  44. Egan, M. E., Glockner-Pagel, J., Ambrose, C., Cahill, P. A., Pappoe, L., Balamuth, N., Cho, E., Canny, S., Wagner, C. A., Geibel, J., and Caplan, M. J. (2002) Nat. Med. 8, 485-492[CrossRef][Medline] [Order article via Infotrieve]
  45. Egan, M. E., Pearson, M., Weiner, S. A., Rajendran, V., Rubin, D., Glockner-Pagel, J., Canny, S., Du, K., Lukacs, G. L., and Caplan, M. J. (2004) Science 304, 600-602[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Miyaji, N. Echigo, M. Hiasa, S. Senoh, H. Omote, and Y. Moriyama
Identification of a vesicular aspartate transporter
PNAS, August 19, 2008; 105(33): 11720 - 11724.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. A. Long, E. Kim, H.-T. Leung, E. Woodruff III, L. An, R. W. Doerge, W. L. Pak, and K. Broadie
Presynaptic Calcium Channel Localization and Calcium-Dependent Synaptic Vesicle Exocytosis Regulated by the Fuseless Protein
J. Neurosci., April 2, 2008; 28(14): 3668 - 3682.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. Isaev, E. Isaeva, T. Shatskih, Q. Zhao, N. C. Smits, N. W. Shworak, R. Khazipov, and G. L. Holmes
Role of Extracellular Sialic Acid in Regulation of Neuronal and Network Excitability in the Rat Hippocampus
J. Neurosci., October 24, 2007; 27(43): 11587 - 11594.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Juge, Y. Yoshida, S. Yatsushiro, H. Omote, and Y. Moriyama
Vesicular Glutamate Transporter Contains Two Independent Transport Machineries
J. Biol. Chem., December 22, 2006; 281(51): 39499 - 39506.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
G Anderson, V V Smith, M Malone, and N J Sebire
Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2500 cases from a single centre
J. Clin. Pathol., December 1, 2005; 58(12): 1305 - 1310.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/2/1408    most recent
M411295200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wreden, C. C.
Right arrow Articles by Reimer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow